Avanir Pharmaceuticals Announces Positive Results of Phase III
Study for Zenvia in Diabetic Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - Avanir
Pharmaceuticals (NASDAQ:AVNR) today announced positive top-line
results from the company's Phase III clinical trial evaluating the
investigational drug Zenvia(TM) (dextromethorphan
hydrobromide/quinidine sulfate ("DMQ")), an NMDA antagonis...
AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic
Peripheral Neuropathic Pain at Second International Congress on
Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIR
Pharmaceuticals (NASDAQ:AVNR) today announced Phase III data on the
efficacy, safety and improvements in patient-centered outcomes in
patients with diabetic peripheral neuropathic (DPN) pain treated
with the investigational drug Zenvia(TM) ...
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic
Peripheral Neuropathic Pain at International Congress on
Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIR
Pharmaceuticals (NASDAQ:AVNR) today announced the presentation of
Phase III data, including efficacy, safety and improvements in
patient-centered outcomes in patients with diabetic peripheral
neuropathic (DPN) pain treated with the investig...
Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia
Long-Term Safety Data at AAN Annual Meeting
... Highlights session on Thursday, May 3, 2007.
zenvia investigator Daniel Wynn, MD, ABSM, Co-Director of...ious neurologic diseases or
injuries, treated with
zenvia for 52 weeks or longer. Results
indicated that adv...hase of the study. The median compliance rate
with
zenvia therapy was 97.1%.
Linda Werling, Ph.D., Directo...